1 In a clinical trial , the participants with BMI 30 or more, or 27 or more with at least one weight-related condition, the average participant lost 20.9% of body weight during the 72-week trial.
2 In a clinical trial , the participants with BMI 30 or more, or 27 or more with at least one weight-related condition, the average participant lost 20.9% of body weight during the 72-week trial.
*Important Notice: The recognized brand name medication approved by the FDA, Zepbound™, Mounjaro®, Wegovy® & Ozempic®, is manufactured by Eli Lilly and Company™. We do NOT manufacture this medication and have no
direct affiliation with Eli Lilly and Company™. However, we give clients the option to choose this
medication and supply it through our partner pharmacies.
Regarding compounded medications, our company works with sterile
compounding pharmacies. These facilities undergo strict inspections, but because the compounded
pharmaceuticals they produce are made according to a prescription from a specific practitioner for a
particular patient, they are not FDA-approved. It might be challenging to directly compare the
results and risk profiles of FDA-approved and compounded pharmaceuticals due to differences in
strength, dose, and other factors. The medical judgment of a licensed clinician, based on a
telemedicine interaction and medical history, determines the prescription of any compounded
medication.
100% money back guarantee if your prescription is not approved; brightmeds.com does not
directly offer medical or pharmacy services. We partner with medical professionals who use
HIPAA-compliant platforms to deliver services. This website’s content is meant only as a source of
information; it should not be used as a substitute of expert medical advice, evaluation, or care. Please
contact your doctor if you have any questions or concerns regarding your health.
